| Document |
Document Title |
|
WO/2006/054624A1 |
It is intended to provide an adhesion preventive by which the adhesion of the surface of an organ can be effectively prevented and which is absorbed in the body, has a high safety, can be easily produced and, therefore, is highly useful ...
|
|
WO/2006/045963A2 |
The invention relates to a composition of cosmetic or pharmacological application for stimulation of synthesis of collagen, in particular, for stimulation of restructuring of the skin. According to the invention, the composition comprise...
|
|
WO/2006/042186A2 |
|
|
WO/2006/032144A1 |
Compositions and methods for the treatment, prevention, inhibition, etc, of inflammatory disease or fibrous adhesions involving administration of fucans from various echinoderm sources, alone or in combination with other agents useful fo...
|
|
WO/2006/032143A1 |
Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc, of inflammatory disease or fibrous adhesions using low sulphate fucans and , if desired, one or more other anti-inflammato...
|
|
WO/2005/102319A2 |
The invention relates to pharmaceutical composition and the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or m...
|
|
WO/2005/097814A2 |
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject...
|
|
WO/2005/094912A1 |
It is intended to provide a graft for transplantation which promotes angiogenesis and has the capacity for self-development in treating an injured vital organ, tissue, etc. It has been considered that a graft for plantation should contai...
|
|
WO/2005/087289A1 |
An adhesion preventive material comprising a crosslinkable polysaccharide derivative which has, incorporated in a polysaccharide side chain, at least one active ester group reactive with an active-hydrogen-containing group and which, upo...
|
|
WO/2005/063278A1 |
The invention relates to a biodegradable barrier network comprising at least two polypeptides, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create sa...
|
|
WO/2005/027933A1 |
The present invention relates generally to a method for providing formation, ultrafiltration and/or lubrication between two or more opposing or in contact surfaces. More particularly, the present invention effects one or more of surface ...
|
|
WO/2005/021011A1 |
The invention describes the use of surfactant comprising phospholipids and pulmonary surfactant proteins for the treatment of surgical adhesions.
|
|
WO/2005/016514A2 |
Methods are disclosed for providing a library of composite or novel composition samples on a support. The method involves depositing one or more components as concentration gradients on the surface of the support. The concentration gradi...
|
|
WO/2005/013691A1 |
Boranocarbonates are described for administration to a human or other mammal for delivery of carbon monoxide. The boranocarbonate is a compound or ion adapted to make CO available for physiological effect, and may be administered with a ...
|
|
WO/2005/009971A1 |
A platelet aggregation inhibitor which contains a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient; and a novel quinolone derivative or a pharmaceutically acceptable salt thereof which are useful...
|
|
WO/2005/009480A2 |
Genitourinary system disorders are treated with therapeutic agents, and optionally further with radiation treatments. One aspect of the invention provides a drug delivery device comprising a codrug or a pharmaceutically acceptable salt o...
|
|
WO/2005/007211A2 |
Methods, compositions and devices for inhibiting restenosis are provided. Specifically, proteasome inhibitor compositions and medical devices useful for the site specific delivery of proteasome inhibitors are disclosed. In one embodiment...
|
|
WO/2004/108179A1 |
A method of using a substantially non-porous equine collagen foil to repair and regenerate dura mater tissue of mammals when the dura mater tissue is damaged as a result of injury, tumors, surgery, and the like. The non-porous equine col...
|
|
WO/2004/081042A2 |
The invention relates to genes of a SNSR family receptors (specific sensory neurone receptors) which are essentially associated with pathological pain conditions, in particular in chronic pains. Said invention relates, in particular to a...
|
|
WO/2004/078210A1 |
It is found out that an oligonucleotide inhibiting the expression of midkine or an antibody inhibiting the effect of midkine is usable in preventing intraperitoneal postoperative adhesion.
|
|
WO2004035070A9 |
Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use.
|
|
WO/2004/069276A1 |
It is intended to provide a drug by which adhesion can be effectively prevented, regulated or treated in cases with the risk of visceral fusion caused by injury, inflammation, etc. before or after various surgical steps such as orthopedi...
|
|
WO/2004/060261A2 |
The invention relates to the novel compounds of formula (I): These compounds are potent factor VIIa inhibitors and are therefore particularly useful for the treatment and/or the prophylaxis of thromboses, apoplexy, cardiac infarction, in...
|
|
WO/2004/056180A1 |
The present invention relates to a composition for arresting, protecting or preserving a cell, tissue or organ comprising an effective amount of a local anaesthetic and of one or more of an anti-adrenergic, a calcium antagonist, an opioi...
|
|
WO/2004/056181A1 |
The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and ...
|
|
WO/2004/052352A1 |
The invention relates to a formulation, which can be administered gastro-intestinally, containing green tea extract and at least one NO donor, which is a substrate of NO synthetase and/or a precursor of said donor. Said formulation is ad...
|
|
WO/2004/050056A1 |
Devices for the delivery of a bioactive substance to a cochlea and methods of delivery thereof. The devices include means to allow the release of the bioactive substance within a cochlea.
|
|
WO/2004/039395A1 |
An immunoevasive agent takes advantage of expression of TNF-related apoptosis-inducing ligand (TRAIL) and allows grafts to evade host's immunity in organ transplantation. Also provided is a method for suppressing rejection in organ trans...
|
|
WO/2004/037280A1 |
It is intended to provide an angiogenesis inducer which is made of fibrin and safe to a living body characterized by, when administered to the living body, being capable of safely inducing angiogenesis to thereby regenerate the functions...
|
|
WO/2004/035011A2 |
Methods for facilitating various dental treatments, therapies and procedures by administration of a Clostridial toxin to a muscle or other tissue on the head or neck of a patient.
|
|
WO/2004/033681A1 |
It is intended to provide a method of screening a compound relating to platelet aggregation by using gp44 which is a factor relating to platelet aggregation, an activity measurement method, a compound obtained by the above method, a kit ...
|
|
WO/2004/026320A1 |
Fluorosilicone fluids useful as high-density fluid ocular tamponades and methods of producing, purifying and using the fluorosilicone fluids in an ocular surgical procedure for retinal treatment.
|
|
WO/2004/024168A1 |
The nutritional deficiencies which constitute a serious side-effect of intestinal cleansing procedures can be alleviated or entirely avoided by a composition and method according to the present invention, wherein a complex carbohydrate i...
|
|
WO/2004/020415A1 |
The invention provides compounds of formula (I) in which L, X, Y, Z1, Z2, R1, R2, R3 and G2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for prepa...
|
|
WO/2004/020435A1 |
The invention is directed to piperidinyl compounds of formula (I) and (II) that selectively bind integrin receptors and methods for treating an integrin mediated disorder, wherein W, R2, Z and q are described in the application.
|
|
WO/2004/018430A1 |
A compound represented by the following formula (I); a pharmaceutically acceptable salt of the compound; and a solvate thereof. [In the formula (I), X represents CH or N; Z represents -O-, -NH-, or -C(=O)-; R and R' each represents hydro...
|
|
WO/2004/017948A2 |
The invention relates to a method of treating immunologc diseases or pathological conditions involving an immunologc component using Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination wit...
|
|
WO/2004/018434A1 |
The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an i...
|
|
WO2002089675A9 |
A wound closure system and methods utilizes a patient's own blood. The system preferably includes a chamber with a needle and a plunger for transferring and storing blood prior to surgery and the use of reversible anticoagulants. The cha...
|
|
WO/2004/014844A2 |
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists,...
|
|
WO/2004/013138A2 |
The invention relates to novel imidazopyridine derivatives which are inhibitors of the transforming growth factor, ('TGF')-ß signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like k...
|
|
WO/2004/002533A1 |
A parenterally deliverable pharmaceutical composition comprises a water soluble parecoxib salt, in dissolved and/or solubilized form in a solvent liquid that comprises water and one or more nonaqueous solubilizer(s). Valdecoxib formed by...
|
|
WO/2004/000331A1 |
The present invention relates to a composition for controlling viability of a tissue including a potassium channel opener or adenosine receptor agonist, a compound for inducing local anaesthesia and a compound for reducing the uptake of ...
|
|
WO/2004/001020A2 |
The present invention relates to epidermal growth factor (EGF) producing lactic acid bacteria and their use to increase intestinal villi height and to promote gut absorption. In particular, the invention relates to EGF producing Lactococ...
|
|
WO/2003/105666A2 |
Methods useful for preventing, limiting, or treating ischemia reperfusion injury in a mammal are disclosed. More particularly, this invention relates to administering A2b adenosine receptor antagonists to prevent, limit or treat ischemia...
|
|
WO/2003/104807A1 |
The use of corticotroph-derived glycoprotein hormone (CGH) to potentiate glucocorticoid action and to reduce glucocorticoid-induced adrenocortical suppression is described. CGH can be co-administered with glucocorticoids to enable a lowe...
|
|
WO/2003/103640A1 |
The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin including surface stabilizer. The statin particles of the composition have an effective average particle size of less t...
|
|
WO/2003/103475A2 |
Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g., c...
|
|
WO/2003/103575A2 |
Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
WO/2003/101424A1 |
A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R¿1? represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R¿2? represents hydrogen, hydroxy, methox...
|
